Medical Affairs, Sanofi India Limited, Mumbai, India.
Pharmaceut Med. 2021 Jul;35(4):197-202. doi: 10.1007/s40290-021-00392-x. Epub 2021 Jul 5.
The medical affairs function represents one of the scientific interfaces in a pharmaceutical organization. Over the last two decades, medical affairs has evolved from being a support function to a strategic pillar within organizational business units. The COVID-19 pandemic has given rise to unforeseen circumstances resulting in a dramatic change in external stakeholder engagements, catapulting the medical affairs function into leading the way on scientific engagements and patient-centric endeavors. The changes in stakeholder interactions and behavior as a result of the pandemic last year are likely to persist in the foreseeable future for which medical affairs professionals need to enhance existing skill sets and acquire expertise in newer domains. In this paper, the transformation of the medical affairs team to a key strategic partner and the skills required to strengthen this transition, in the next normal of a post-COVID world, is explored.
医学事务职能代表了制药组织中的一个科学接口。在过去的二十年中,医学事务已经从支持性功能演变为组织业务部门的战略支柱。COVID-19 大流行带来了意想不到的情况,导致外部利益相关者的参与发生了巨大变化,使医学事务职能部门在科学参与和以患者为中心的努力方面处于领先地位。去年大流行导致的利益相关者互动和行为的变化可能在可预见的未来持续存在,为此,医学事务专业人员需要增强现有技能,并在 COVID-19 之后的新常态下获得新领域的专业知识。本文探讨了医学事务团队如何向关键战略合作伙伴转型,以及在 COVID-19 之后的新常态下,需要哪些技能来加强这种转型。